Skip to main content

We need more new antibiotics

By Helen Boucher, Special to CNN
June 13, 2013 -- Updated 2243 GMT (0643 HKT)
STORY HIGHLIGHTS
  • Obama administration is considering streamlining the approval process for antibiotics
  • Helen Boucher: For patients with life-threatening infections, access to new antibiotics is vital
  • She says by limiting their use to the sickest of the sick, we can minimize risks of new drugs
  • Boucher: We need to encourage more companies to do antibiotic research and development

Editor's note: Helen Boucher is director of the infectious diseases fellowship program and staff physician at Tufts Medical Center, and associate professor of medicine at Tufts University School of Medicine. She is a member of the Infectious Diseases Society of America's Antimicrobial Resistance Committee and serves in advisory roles related to antibiotic development for some pharmaceutical companies.

(CNN) -- For desperately ill patients with serious, life-threatening antibiotic-resistant infections, access to new antibiotics is a matter of life and death.

All across America, people are dying from bacterial infections that we used to be able to cure with antibiotics.

Just this March, the Centers for Disease Control and Prevention warned the public about a four-fold increase in one group of "nightmare bacteria," carbapenem-resistant Enterobacteriaceae, which kills up to 50% of the people infected, and is on the rise. The annual impact of antibiotic resistant infections on the U.S. health care system is estimated to be $21 billion to $34 billion in excess health care costs and more than 8 million additional hospital days. At the same time, we are not making new antibiotics fast enough to prevent these deaths.

Without new antibiotics, things we all take for granted, including surgery, chemotherapy, organ transplantation and premature infant care, will be in jeopardy. A streamlined but targeted approach that speeds regulatory approval of new antibiotics -- and limits their use to the sickest of the sick -- is an appropriate way to balance the safety risks of these new drugs with the lifesaving benefits they can offer patients who have no other treatment options.

Helen Boucher
Helen Boucher

As a practicing infectious disease physician, my colleagues and I are seeing firsthand the devastating effects that resistant infections have on patients.

Consider Addie Rerecich, who was a healthy, athletic 11-year-old in 2011 before she spent five months in an Arizona hospital battling several serious drug-resistant infections that her doctors did not have antibiotics powerful enough to treat. Addie ultimately needed a double lung transplant to save her life. The health care costs from her hospital stay alone totaled $6 million, and she will need medical attention and therapy for the rest of her life.

As resistant infections like those that nearly took Addie's life continue to increase, the antibiotic pipeline is nearly dry, with few drugs in development that will work against the most alarming pathogens our patients face.

A proposal from the Infectious Diseases Society of America aims to address a key part of the problem by reducing the obstacles to regulatory approval of new antibiotics for use in a distinct, narrow group of people: Patients with serious resistant infections that have no effective treatment options left.

How will this make a difference?

The current regulatory environment in the U.S. discourages drug companies from antibiotic research and development, and few firms are active in this area today. Antibiotics also aren't as profitable as other drugs, such as those for chronic conditions like heart disease or diabetes, which patients often take for years. A more direct path for regulatory approval can encourage more companies to get involved in antibiotic development again.

IDSA's approach -- the Limited Population Antibacterial Drug -- would speed patients' access to new, lifesaving antibiotics by allowing the Food and Drug Administration to approve them for narrow use based on smaller clinical trials than required for more widely used antibiotics. Under LPAD, drug companies will still have to show that a drug's benefits outweigh the risks in patients with serious infections. It's an idea modeled after the successful Orphan Drug Program, which encourages the development of drugs for rare diseases.

Promoting the appropriate use of these new antibiotics is critical, because we know antibiotic misuse and overuse are significant drivers of drug resistance.

Special labeling will ensure narrow marketing of these drugs. Educational efforts should be put in place to send a strong signal to health care providers, facilities and insurers that these drugs are only for patients who need them most. These drugs will also likely be priced higher, commensurate with their value as life-saving medicines, than traditionally approved antibiotics, another factor that will help limit their wider use.

Antibiotic stewardship programs, which encourage appropriate antibiotic use by providers and health facilities, will play a key role. These programs provide much needed support and guidance to clinicians and ensure that our precious resource of antibiotics will be used wisely.

Professional medical groups -- including the American Medical Association -- public health organizations, patient groups and pharmaceutical manufacturers have voiced their support for IDSA's proposal. FDA and several members of Congress are also interested in the concept and in moving it forward.

To be sure, developing new antibiotics and speeding their approval process to treat seriously ill patients is just one way to grapple with this complex public health crisis.

IDSA also promotes enhanced public health efforts, including better data collection and surveillance of drug resistance and the use of antibiotics, improved infection prevention, antimicrobial stewardship, and stronger efforts to encourage the appropriate use of antibiotics in humans and on the farm. Increased research funding to explore how antibiotic resistance develops and spreads is just as vital, along with additional economic incentives and regulatory clarity to boost antibiotic development.

Patients like Addie need our help. We must take action now.

Follow @CNNOpinion on Twitter.

Join us at Facebook/CNNOpinion.

The opinions expressed in this commentary are solely those of Helen Boucher.

ADVERTISEMENT
Part of complete coverage on
August 22, 2014 -- Updated 1231 GMT (2031 HKT)
James Dawes says calling ISIS evil over and over again could very well make it harder to stop them.
August 22, 2014 -- Updated 1223 GMT (2023 HKT)
Retired Lt. Gen. Mark Hertling says he learned that the territory ISIS wants to control is amazingly complex.
August 21, 2014 -- Updated 1450 GMT (2250 HKT)
David Weinberger says Twitter and other social networks have been vested with a responsibility, and a trust, they did not ask for.
August 22, 2014 -- Updated 1103 GMT (1903 HKT)
John Inazu says the slogan "We are Ferguson" is meant to express empathy and solidarity. It's not true: Not all of us live in those circumstances. But we all made them.
August 20, 2014 -- Updated 1951 GMT (0351 HKT)
Cerue Garlo says Liberia is desperate for help amid a Ebola outbreak that has touched every aspect of life.
August 21, 2014 -- Updated 1742 GMT (0142 HKT)
Eric Liu says Republicans who want to restrict voting may win now, but the party will suffer in the long term.
August 21, 2014 -- Updated 1538 GMT (2338 HKT)
Jay Parini: Jesus, Pope and now researchers agree: Wealth decreases our ability to sympathize with the poor.
August 21, 2014 -- Updated 1200 GMT (2000 HKT)
Judy Melinek offers a medical examiner's perspective on what happens when police kill people like Michael Brown.
August 19, 2014 -- Updated 2203 GMT (0603 HKT)
It used to be billy clubs, fire hoses and snarling German shepherds. Now it's armored personnel carriers and flash-bang grenades, writes Kara Dansky.
August 20, 2014 -- Updated 1727 GMT (0127 HKT)
Maria Haberfeld: People who are unfamiliar with police work can reasonably ask, why was an unarmed man shot so many times, and why was deadly force used at all?
August 18, 2014 -- Updated 2152 GMT (0552 HKT)
Ruben Navarrette notes that this fall, minority students will outnumber white students at America's public schools.
August 19, 2014 -- Updated 2121 GMT (0521 HKT)
Humans have driven to extinction four marine mammal species in modern times. As you read this, we are on the brink of losing the fifth, write three experts.
August 19, 2014 -- Updated 1158 GMT (1958 HKT)
It's been ten days since Michael Brown was killed, and his family is still waiting for information from investigators about what happened to their young man, writes Mel Robbins
August 18, 2014 -- Updated 1242 GMT (2042 HKT)
The former U.K. prime minister and current U.N. envoy says there are 500 days left to fulfill the Millennium Goals' promise to children.
August 20, 2014 -- Updated 1738 GMT (0138 HKT)
Peter Bergen says the terror group is a huge threat in Iraq but only a potential one in the U.S.
August 18, 2014 -- Updated 2006 GMT (0406 HKT)
Pepper Schwartz asks why young women are so entranced with Kardashian, who's putting together a 352-page book of selfies
ADVERTISEMENT